Clinical Intergroup – Literatur

Mantle cell lymphomas

W. Hiddemann, M. Dreyling, M. Tiemann, C. Schrader , M. Unterhalt for the European Mantle Cell Study Group: Mantle cell lymphomas. Haematologica 84: 93-95, 1999

Rituximab plus chemotherapy in follicular and mantle cell lymphomas

W Hiddemann, M Dreyling, M Unterhalt: Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 81 (Suppl 2): 16-20, 2003

Mantle cell lymphoma: established therapeutic options and future directions

G. Lenz, M. Dreyling, W. Hiddemann: Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 83: 71-77, 2004

Mantle Cell Lymphoma: Therapeutic strategies are different from CLL

W Hiddemann, M Dreyling: Mantle Cell Lymphoma: Therapeutic strategies are different from CLL.Curr Treat Options Oncol 4(3): 219-26, 2003

Role of monoclonal antibodies in the treatment of follicular and mantle cell lymphoma

M Dreyling, M Unterhalt, W Hiddemann: Role of monoclonal antibodies in the treatment of follicular and mantle cell lymphoma. Hematology J 4 (Suppl. 3): 191-194, 2003.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group

R Forstpointner, M Dreyling, R Repp, S Hermann., A Hänel, B Metzner, C Pott, F Hartmann, F Rothmann, R Rohrberg, H-P Böck, H Wandt, M Unterhalt, W Hiddemann: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group Blood 104: 3064-1071, 2004

The role of fludarabine in the treatment of follicular and mantle cell lymphoma.

G. Lenz, W. Hiddemann, M. Dreyling: The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 101: 883-893, 2004

Current strategies in the treatment of advanced stage mantle cell lymphoma.

Lenz G, Dreyling M, Unterhalt M, Hiddemann W. Current strategies in the treatment of advanced stage mantle cell lymphoma. Dtsch Med Wochenschr 129(45):2429-33, 2004

Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous Stem Cell Transplantation in First Remission significantly prolongs Progression-Free Survival in Mantle Cell Lymphoma - Results of a Prospective Randomized Trial of the European MCL Network.

M. Dreyling, G. Lenz, E. Hoster, A. Van Hoof, C. Gisselbrecht, R. Schmits, B. Metzner, L. Truemper, M. Reiser, H. Steinhauer, J. Boiron, M.Boogaerts, A. Aldaoud, , V. Silingardi, H. Kluin-Nelemans, J. Hasford, R. Parwaresch, M. Unterhalt and W. Hiddemann: Early Consolidation by Myeloablative Radiochemotherapy followed by Autologous Stem Cell Transplantation in First Remission significantly prolongs Progression-Free Survival in Mantle Cell Lymphoma - Results of a Prospective Randomized Trial of the European MCL Network. Blood 105: 2677-2684, 2005

Immuno-Chemotherapy with Rituximab and CHOP significantly improves Response and Time to Treatment Failure but not long-term Outcome in Patients with previously untreated Mantle Cell Lymphoma – Results of a prospective randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

G. Lenz, M. Dreyling, E. Hoster, B. Wörmann, U. Dührsen, B. Metzner, H. Eimermacher, A. Neubauer, H. Wandt, H. Steinhauer, S. Martin, El. Heidemann, A. Aldaoud, R. Parwaresch, J. Hasford, M. Unterhalt and W. Hiddemann: Immuno-Chemotherapy with Rituximab and CHOP significantly improves Response and Time to Treatment Failure but not long-term Outcome in Patients with previously untreated Mantle Cell Lymphoma – Results of a prospective randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23: 1984-1992, 2005

Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL?

Lenz G, Dreyling M: Does the combination of rituximab and thalidomide influence the long-term perspectives of advanced-stage MCL? Nat Clin Pract Oncol 2005; 2: 72-73.

Mantle cell lymphoma and other t(11;14) disorders: How biology can drive therapy

Dreyling M, Bergsagel PL, Gordon LI, Cotter FE: Mantle cell lymphoma and other t(11;14) disorders: How biology can drive therapy. ASCO Educational book 2006, 476-484

Maintenance Therapy with Rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of Rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas – Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Forstpointner R, Unterhalt M, Dreyling M, Böck H-P, Repp R, Wandt H, Pott C, Seymour J, Metzner B, Hänel A, Lehmann T, Hartmann F, Einsele H, Hiddemann W: Maintenance Therapy with Rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of Rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas – Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006 108(13):4003-4008

Revised Response Criteria for Malignant Lymphoma

Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V. Revised Response Criteria for Malignant Lymphoma. J Clin Onco. 2007; 25(5):579-86.

Therapy of mantle cell lymphoma.

Dreyling M, Unterhalt M, Weigert O, Hiddemann W. Therapy of mantle cell lymphoma. Internist (Berl). 2007; 48: 382-388.

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.

Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A:Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007 May 2;99(9):706-14.

Current management of mantle cell lymphoma.

Weigert O, Unterhalt M, Hiddemann W, Dreyling M: Current management of mantle cell lymphoma. Drugs 2007:1689-702

Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network

Hermine at al., ASH 2010

The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

Dreyling M, Ferrero S; European Mantle Cell Lymphoma Network. Haematologica. 2016 Feb;101(2):104-14. (IF 6,53)

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL network phase II trial.

Ferrero S, Pastore A, Scholz CW, Forstpointner R, Pezzutto A, Bergmann L, Trümper L, Finke J, Keller U, Ghione P, Passera R, Hiddemann W, Weigert O, Unterhalt M, Dreyling M Leukemia. 2016 Apr;30(4):984-7 (IF 9,38)

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Lancet. 2016;387:770-8 (IF 45,22)

Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network. Lancet. 2016 Aug 6;388(10044):565-75. (IF 45,22)

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials.

Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O. Leukemia. 2016;30(6):1428-30 (IF 9,38)

Post-ibrutinib outcomes in patients with mantle cell lymphoma.

Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Blood. 2016 Mar 24;127(12):1559-63 (IF 10,56)

Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.

Kahl BS, Dreyling M, Gordon LI, Quintanilla-Martinez L, Sotomayor EM Leuk Lymphoma. 2017 Jan 31:1-12. [Epub ahead of print] (IF 2,49)

Studiengruppen der Clinical Intergroup »